PLSE
Pulse Biosciences, Inc.14.23
+0.10+0.71%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
964.33MP/E (TTM)
-Basic EPS (TTM)
-1.14Dividend Yield
0%Recent Filings
8-K
Stockholders re-elect full board
Pulse Biosciences stockholders at the December 9, 2025 annual meeting unanimously elected six directors—Duggan, LaViolette, Soni, Uecker, van den Broek, and Zanganeh—each garnering over 52 million 'For' votes amid 9.9 million broker non-votes. They ratified Deloitte & Touche as auditors for fiscal 2025 with near-unanimous support, approved executive pay on a say-on-pay vote, and opted for triennial frequency going forward. All six won decisively.
8-K
MD Anderson thyroid trial starts
Pulse Biosciences launched a research collaboration with MD Anderson Cancer Center on December 9, 2025, to test its FDA-cleared nPulse Vybrance Percutaneous Electrode System for thyroid cancers. FDA approved the IDE for a first-in-human feasibility study on papillary thyroid microcarcinoma, enrolling 30 subjects at two sites starting early 2026. Preclinical work targets deadly anaplastic thyroid carcinoma. nsPFA promises nonthermal ablation. Trial success uncertain.
8-K
Investor deck update posted
10-Q
Q3 FY2025 results
Pulse Biosciences notched its first product revenue of $86K in Q3 2025 from Vybrance Percutaneous Electrode System sales (y/y from $0), yet posted a $20.4M operating loss, up 49% y/y (derived), and $19.4M net loss versus $12.7M last year—widened by $16.5M stock-based comp within $5.6M total. Cash burned $39.4M in operating activities over nine months ended September 30, leaving $95.2M on hand after $16.8M financing inflows, mainly warrant exercises. Vybrance pilots hit 200+ procedures; cardiac programs advance with IDE approvals. Cash funds a year ahead. Intense competition shadows adoption.
8-K
Q3 revenue starts; trials advance
Pulse Biosciences posted $86 thousand Q3 revenue from nPulse Vybrance limited release, treating over 200 patients. FDA IDE approval launched NANOCLAMP AF study for surgical AF ablation; PRECISE-BTN thyroid trial hit 40% enrollment. GAAP net loss widened to $19.4 million on $20.5 million expenses, yet cash holds at $95.2 million. Progress accelerates nsPFA validation.
IPO
Employees
Sector
Industry
ATRC
AtriCure, Inc.
41.08+0.04
BSX
Boston Scientific Corporation
92.95+0.76
EMED
Electromedical Technologies, In
0.00+0.00
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
HBIO
Harvard Bioscience, Inc.
0.70-0.00
HSCS
HeartSciences Inc.
2.31-0.16
PACB
Pacific Biosciences of Californ
2.02-0.10
PROF
Profound Medical Corp.
7.55-0.14
SSKN
Strata Skin Sciences, Inc.
1.33-0.03
STME
Stimcell Energetics, Inc.
0.37-0.04